New Medicine - FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa

[pioneer]

FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa

The U.S. Food and Drug Administration (FDA) has evaluated new information about the risk of serious bleeding associated with use of the anticoagulants (blood thinners) dabigatran (Pradaxa) and warfarin (Coumadin, Jantoven, and generics).

Source: FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa